Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan.
Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei City, Taiwan.
Cell Transplant. 2021 Jan-Dec;30:9636897211052300. doi: 10.1177/09636897211052300.
Amphetamine-type stimulants have become important and popular abused drugs worldwide. Methamphetamine (Meth) sensitization, characterized by a progressive increase in behavioral responses after repeated administration, has been reported in rodents and patients. This behavioral effect has been used as a laboratory model to study drug addiction and schizophrenia. The mesolimbic dopaminergic pathway plays a significant role in the development of Meth behavioral sensitization. Previous studies have reported that the ablation of nucleus accumbens (NAc) by electrolytic or thermal lesioning attenuates addictive behavior to opioids in animals. However, these studies were only conducted in opioid addictive rodents. Furthermore, these ablation procedures also damaged the non-dopaminergic neurons and fibers passing through the NAc. The purpose of this study was to examine the therapeutic effect of NAc lesioning by a selective dopaminergic toxin in Meth-sensitized animals. Adult mice received repeated administration of Meth for 7 days. Open-field locomotor activity and stereotype behavior were significantly increased after Meth treatment, suggesting behavior sensitization. A partial lesion of dopaminergic terminals was made through stereotaxic administration of dopaminergic toxin 6-hydroxydopamine (6-OHDA) to the NAc in the Meth -sensitized mice. Meth behavioral sensitization was significantly antagonized after the lesioning. Brain tissue was collected for qRT-PCR analysis. Repeated administration of Meth increased the expression of tyrosine hydroxylase (TH), BDNF, and Shati, a marker for Meth sensitization, in the NAc. Treatment with 6-OHDA significantly antagonized the upregulation of TH and Shati. Taken together, these data suggest that local administration of 6-OHDA mitigated Meth sensitization in chronic Meth-treated animals. Our data support a new surgical treatment strategy for Meth abuse.
苯丙胺类兴奋剂已成为全球重要且流行的滥用药物。在啮齿动物和患者中已经报道了反复给予后行为反应逐渐增加的苯丙胺(Meth)敏化。这种行为效应已被用作研究药物成瘾和精神分裂症的实验室模型。中脑边缘多巴胺能通路在 Meth 行为敏化的发展中起重要作用。先前的研究报告称,通过电解或热损伤破坏伏隔核(NAc)可减轻动物对阿片类药物的成瘾行为。然而,这些研究仅在阿片类药物成瘾的啮齿动物中进行。此外,这些消融程序还损伤了通过 NAc 的非多巴胺能神经元和纤维。本研究的目的是检查 NAc 消融对 Meth 敏化动物的治疗效果。成年小鼠接受 Meth 重复给药 7 天。Meth 处理后,旷场运动活动和刻板行为明显增加,表明行为敏化。通过立体定向给予多巴胺能毒素 6-羟多巴胺(6-OHDA)对 Meth 敏化小鼠的 NAc 进行部分多巴胺能末梢消融。消融后,Meth 的行为敏化明显受到拮抗。收集脑组织进行 qRT-PCR 分析。反复给予 Meth 增加了 NAc 中酪氨酸羟化酶(TH)、BDNF 和 Shati 的表达,Shati 是 Meth 敏化的标志物。6-OHDA 的治疗显著拮抗了 TH 和 Shati 的上调。总之,这些数据表明,6-OHDA 的局部给药减轻了慢性 Meth 处理动物的 Meth 敏化。我们的数据支持一种治疗 Meth 滥用的新手术治疗策略。